ASCVD Clinical Research Updates

Series Program Overview

Emerging evidence and scientific advancements are revealing pathophysiologic mechanisms correlated with systemic inflammation and the development of atherosclerotic cardiovascular disease (ASCVD). Patients with chronic kidney disease (CKD) are at high risk for developing ASCVD. Novel anti-inflammatory therapies are showing efficacy at reducing inflammation and development of ASCVD, and are adding to the treatment options beyond the usual lipid-lowering agents.  As new clinical evidence and targeted therapies emerge, cardiologists, nephrologists, and other clinicians who care for patients with CKD need to stay up to date on the changing treatment paradigm for reducing risk of ASCVD.  During this Clinical Research Updates™ activity, our expert faculty share cardiology and nephrology perspectives and insights into how best to incorporate these new and emerging treatments in busy clinical practices worldwide. This forward-looking CME program aims to capture expert interpretations of new and emerging therapies for reducing systemic inflammation, including the published evidence to support them, to help cardiologists, nephrologists, and other clinicians reduce the risk of development of ASCVD in their patients living with CKD.

Target Audience

The educational design of this activity addresses the needs of cardiologists and a secondary audience of nephrologists, as well as to other healthcare providers (HCPs) involved in the care of patients at risk for developing atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).